Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback